Affordable Access

Access to the full text

Development of a fully automated high throughput PCR for the detection of SARS-CoV-2: The need for speed

Authors
  • Mayer, Florian J.1
  • Ratzinger, Franz2
  • Schmidt, Ralf L.J.1
  • Greiner, Georg1
  • Landt, Olfert3
  • Am Ende, Alexander3
  • Corman, Victor M.4
  • Perkmann-Nagele, Nicole1
  • Watkins-Riedel, Thomas1
  • Petermann, Dagmar1
  • Abadir, Karoline5
  • Zweimüller-Mayer, Josef5
  • Strassl, Robert1
  • 1 Medical University of Vienna, Austria , (Austria)
  • 2 Medical Diagnostic Laboratories, Austria , (Austria)
  • 3 Tib-Molbiol, Germany , (Germany)
  • 4 Berlin, Germany and German Centre for Infection Research (DZIF), Germany , (Germany)
  • 5 QIAGEN GmbH, Austria , (Austria)
Type
Published Article
Journal
Virulence
Publisher
Landes Bioscience
Publication Date
Jul 29, 2020
Volume
11
Issue
1
Pages
964–967
Identifiers
DOI: 10.1080/21505594.2020.1798041
PMID: 32726172
PMCID: PMC7549918
Source
PubMed Central
Keywords
License
Green

Abstract

Currently, testing for coronavirus is performed with time and personnel consuming PCR assays. The aim of this study was to evaluate the sensitivity, specificity and capacity of a fully automated, random access high-throughput real-time PCR-based diagnostic platform for the detection of SARS-CoV-2. The NeuMoDx N96 system displayed an equal or better detection rate for SARS-CoV-2 compared with the LightCycler 480II system and showed a specificity of 100%. The median PCR run time for all 28 PCR runs was 91 (IQR 84–97) minutes. The capacity of the NeuMoDx N96 could easily surpass the capacity of most currently used molecular test systems and significantly reduce the turn-around time.

Report this publication

Statistics

Seen <100 times